Giovanni Martinelli

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Hematol Oncol 24:196-204. 2006
  2. pmc Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Biologics 1:121-7. 2007
  3. ncbi Molecular therapy for multiple myeloma
    G Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 86:908-17. 2001
  4. ncbi Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response
    G Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, S Orsola Hospital, University of Bologna, Italy
    Leuk Lymphoma 39:113-20. 2000
  5. ncbi Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation
    G Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 85:930-4. 2000
  6. ncbi Dual tyrosine kinase inhibitors in chronic myeloid leukemia
    G Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Leukemia 19:1872-9. 2005
  7. ncbi New tyrosine kinase inhibitors in chronic myeloid leukemia
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 90:534-41. 2005
  8. ncbi Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 88:1221-8. 2003
  9. ncbi Bone marrow of a patient with acute non-lymphoblastic leukaemia associated with the t(1;7)(p11;p11) chromosomal translocation
    Giovanni Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    Haematologica 87:EIM08. 2002
  10. ncbi Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one
    Giovanni Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:688-94; discussion 694. 2002

Detail Information

Publications131 found, 100 shown here

  1. ncbi Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Hematol Oncol 24:196-204. 2006
    ..We review current trends in the management of chronic myeloid leukaemia patients undergoing treatment with tyrosine kinase inhibitors...
  2. pmc Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Biologics 1:121-7. 2007
    ..Preliminary studies demonstrated that nilotinib has more efficacy than imatinib in inhibiting proliferation of BCR-ABL-dependent cells, a relatively safety profile and clinical efficacy in all phases of CML...
  3. ncbi Molecular therapy for multiple myeloma
    G Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 86:908-17. 2001
    ..Several molecular and cytogenetic advances have suggested novel therapeutic strategies that could help reach an eventual cure for multiple myeloma (MM)...
  4. ncbi Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response
    G Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, S Orsola Hospital, University of Bologna, Italy
    Leuk Lymphoma 39:113-20. 2000
    ....
  5. ncbi Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation
    G Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 85:930-4. 2000
    ..We assessed the clinical relevance of minimal residual disease (MRD) in 14 MM patients in CR after allografting with PBSC (6 patients) or BM (8 patients)...
  6. ncbi Dual tyrosine kinase inhibitors in chronic myeloid leukemia
    G Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Leukemia 19:1872-9. 2005
    ..Here, we review the development, the mode of action and the preclinical or early clinical evaluation of several novel dual Src and Abl kinase inhibitors...
  7. ncbi New tyrosine kinase inhibitors in chronic myeloid leukemia
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 90:534-41. 2005
    ..This review highlights the development of new TKI as specific molecularly targeted therapy and as the principal mechanisms for overcoming imatinib resistance...
  8. ncbi Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 88:1221-8. 2003
    ..Other genes that have been implicated at the rearrangement breakpoint are GR6 and RPN1 (both on 3q21). The aim of this study was to investigate the expression of the EVI1 fusion genes in AML patients with 3q21q26 syndrome...
  9. ncbi Bone marrow of a patient with acute non-lymphoblastic leukaemia associated with the t(1;7)(p11;p11) chromosomal translocation
    Giovanni Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    Haematologica 87:EIM08. 2002
  10. ncbi Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one
    Giovanni Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:688-94; discussion 694. 2002
    ..We previously described a novel type of the chimeric bcr-abl mRNA transcript in a patient with a Philadelphia chromosome positive chronic myeloid leukemia. A similar bcr-abl transcript has also been described by others...
  11. ncbi Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
    G Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Ann Oncol 17:495-502. 2006
    ....
  12. ncbi Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells
    G Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Haematologica 84:397-404. 1999
    ..We report the clinical and molecular follow-up of 10 MM patients who underwent autologous stem cell transplantation with peripheral blood selected CD34+ cells, as support therapy following a myeloablative conditioning regimen...
  13. ncbi Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma
    G Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    J Clin Oncol 18:2273-81. 2000
    ....
  14. ncbi Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints
    G Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 85:40-6. 2000
    ..We further characterized a novel type of chimeric BCR-ABL mRNA transcript detected in a patient with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML)...
  15. ncbi Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
    ..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317...
  16. ncbi ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
    ....
  17. doi Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
    ..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial...
  18. doi Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Ilaria Iacobucci
    Department of Hematology Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 112:3847-55. 2008
    ..These results establish a previously unknown link between specific molecular defects that involve alternative splicing of the IKZF1 gene and the resistance to TKIs in Ph+ ALL patients...
  19. doi mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
    Manuela Mancini
    Dipartimento di Ematologia e Scienze Oncologiche Lorenzo e Ariosto Seràgnoli, University of Bologna, Italy
    Leuk Res 34:641-8. 2010
    ....
  20. ncbi Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006
    ..CCgR is durable in the majority of patients but relapse occurs in a subset...
  21. ncbi Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis
    Fausto Castagnetti
    Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    J Clin Oncol 28:2748-54. 2010
    ..For this reason, in 2006, the European LeukemiaNet recommendations still considered der(9) deletions as a candidate adverse prognostic factor and required a careful monitoring of the patient...
  22. ncbi Imatinib mesylate in the treatment of hematologic malignancies
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 40138 Bologna, Italy
    Expert Opin Biol Ther 7:1597-611. 2007
    ..In this article, the authors review the evidence which led to imatinib approval in the treatment of several of the above mentioned diseases...
  23. doi RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia
    Manuela Mancini
    Dipartimento di Ematologia e Scienze Oncologiche Lorenzo e Ariosto Seràgnoli, University of Bologna Medical School, Bologna, Italy
    J Cell Biochem 109:320-8. 2010
    ..RAD 001 cytotoxicity on cells not expressing the BCR-ABL fusion gene or its p210 protein tyrosine kinase (TK) activity suggests that the inhibition of normal hematopoiesis may represent a drug side effect...
  24. ncbi Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
    Simona Luatti
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 120:761-7. 2012
    ..The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy...
  25. doi Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leuke
    Ilaria Iacobucci
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 114:2159-67. 2009
    ....
  26. ncbi Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571
    Lucia Mazzacurati
    Istituto di Ematologia e Oncologia Medica Lorenzo e Ariosto Serágnoli, University of Bologna, Medical School, Bologna, Italy
    Hematol J 5:168-77. 2004
    ..In CML, they might further enhance the proliferative advantage and genomic instability of clonal myeloid progenitors featuring a class of poor prognosis patients eventually resistant to STI571...
  27. ncbi Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Chem 50:1205-13. 2004
    ..Point mutations within the ABL kinase domain are emerging as the most frequent mechanism for reactivation of kinase activity within the leukemic clone...
  28. ncbi Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
    Silvia Buonamici
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Blood 99:443-9. 2002
    ..12% might indicate the patient is in a curable state. If confirmed, such thresholds could open the way to a new phase in post-CR therapeutic decision making for patients with inv(16) AML...
  29. ncbi Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
    Michele Baccarani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    Blood 104:4245-51. 2004
    ..The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies...
  30. doi Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
    Simona Soverini
    Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 114:2168-71. 2009
    ....
  31. doi Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
    Fausto Castagnetti
    Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 113:3428-34. 2009
    ..These clinical trials are registered at www.clinicaltrials.gov as no. NCT00510926...
  32. ncbi Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    Blood 102:1588-94. 2003
    ..055). We concluded that cyclin D1 overexpression is closely associated with 11q abnormalities and identifies a subset of MM patients who are more likely to have prolonged duration of remission and EFS following autologous transplantation...
  33. ncbi Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 24:454-9. 2006
    ..Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia...
  34. ncbi First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Res 28:987-90. 2004
    ..Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients...
  35. pmc The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Haematologica 95:1415-9. 2010
    ..78%; P=0.02). These data suggest that the response to the combination treatment is more rapid. It is not yet known how much a rapid reduction will influence the longer-term overall and progression free survival, and the cure rate...
  36. doi Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
    Giulia Marzocchi
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 117:6793-800. 2011
    ..Therefore, we suggest that patients with variant translocations do not constitute a "warning" category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  37. ncbi Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
    Francesca Palandri
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 93:1792-6. 2008
    ..In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients...
  38. doi Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
    Roberto M Lemoli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Blood 114:5191-200. 2009
    ..Moreover, leukemic CD34(-) cells survived exposure to BCR-ABL inhibitors in vivo. Thus, we identified a novel CD34(-) leukemic stem cell subset in CML with peculiar molecular and functional characteristics...
  39. ncbi Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
    Simona Soverini
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:7374-9. 2006
    ..ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients...
  40. ncbi Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology L and A Serànoli, University of Bologna, Italy
    Blood 103:2284-90. 2004
    ..We conclude that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time. Only 1 of 22 negative cases has had a relapse as yet...
  41. ncbi Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission
    Michele Malagola
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 89:ECR25. 2004
  42. ncbi Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer 110:1178-86. 2007
    ..It also has demonstrated promising efficacy in Ph+ ALL but is still being evaluated in phase 2 trials. In this article, the authors reviewed current knowledge on novel tyrosine-kinase inhibitors in adult Ph+ ALL patients...
  43. ncbi The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Haematologica 92:1173-9. 2007
    ..These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate...
  44. doi Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Clin Cancer Res 15:1059-63. 2009
    ..The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of progression-free survival in chronic myeloid leukemia patients treated with imatinib...
  45. pmc IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia
    Ilaria Iacobucci
    Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    PLoS ONE 7:e40934. 2012
    ....
  46. doi Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib
    Simona Soverini
    Department of Hematology Oncology, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Leuk Res 35:1527-9. 2011
    ..Our results suggest that a) Bcr-Abl mutations, even at low level, seem to be very rare in patients in MMR on first-line nilotinib; b) low-level mutations do not always predict for subsequent relapse...
  47. doi Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia
    Matilde Y Follo
    Department of Human Anatomical Sciences, Cellular Signalling Laboratory, University of Bologna, Bologna, Italy
    J Clin Oncol 27:782-90. 2009
    ..To evaluate the association between the presence of phosphoinositide-phospholipase C beta1 (PI-PLCbeta1) mono-allelic deletion with the clinical outcome of myelodysplastic syndromes (MDS) patients...
  48. ncbi Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Haematologica 92:101-5. 2007
    ..As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients...
  49. doi Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
    Francesca Palandri
    Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 93:770-4. 2008
    ..Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance...
  50. doi Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
    Gabriele Gugliotta
    Department of Hematology and Oncology Seràgnoli, University of Bologna S Orsola Malpighi Hospital, Bologna, Italy
    Blood 117:5591-9. 2011
    ..These data show that response to IM was not affected by age and that the mortality rate linked to CML is similar in both age groups. This trial was registered at www.clinicaltrials.gov as #NCT00514488 and #NCT00510926...
  51. pmc Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
    Francesca Palandri
    Department of Hematology and Medical Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:1758-61. 2009
    ..The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited...
  52. pmc Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
    Simona Soverini
    Department of Haematology Oncology, L e A Serígnoli, University of Bologna, Bologna, Italy
    Oncologist 16:868-76. 2011
    ..Here, we discuss the pros and cons of using this approach in TKI selection...
  53. ncbi Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL
    Simona Soverini
    Institute of Haematology and Medical Oncology L e A Seragnoli, University of Bologna, Italy
    Lancet Oncol 8:273-4. 2007
  54. doi Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia
    Michela Palmisano
    Institute of Hematology and Medical Oncology L e A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Hematology 13:1-12. 2008
    ....
  55. ncbi Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606
    Manuela Mancini
    Istituto di Ematologia e Oncologia Medica Lorenzo e Ariosto Serágnoli, University of Bologna Medical School, Via Massarenti 9, 40138 Bologna, Italy
    Leuk Res 31:979-87. 2007
    ..The putative roles of growth factor (namely IL-3) autocrine loop in BCR-ABL-expressing progenitor progression towards a drug-resistant phenotype are discussed...
  56. ncbi Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC
    Michele Bianchini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti no 9, 40138 Bologna, Italy
    Clin Chem 49:1642-50. 2003
    ....
  57. ncbi The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients
    G Visani
    , University of Bologna, Bologna, Italy
    Leukemia 15:903-9. 2001
    ....
  58. ncbi Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr
    Simona Soverini
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Cancer 120:1002-9. 2014
    ....
  59. doi Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 113:4497-504. 2009
    ..This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488...
  60. doi Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'
    Gianantonio Rosti
    Department of Hematology and Oncology L e A Seragnoli, S Orsola Malpighi University Hospital, 9 40138 Bologna, Italy
    Leuk Lymphoma 51:583-91. 2010
    ..This consideration involves the differences in both the imatinib-resistant and -intolerant patients enrolled in the pivotal studies for each agent, as well as other trial criteria...
  61. ncbi Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 92:1721-2. 2007
    ..No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild...
  62. ncbi Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Lymphoma 45:731-3. 2004
    ..In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL...
  63. doi IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report
    Giovanni Martinelli
    Molecular Biology Unit, Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    J Clin Oncol 27:5202-7. 2009
    ....
  64. ncbi Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Serànoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:469-72. 2006
    ....
  65. ncbi Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR37. 2003
  66. ncbi Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 89:236-7. 2004
  67. ncbi PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation
    William L Blalock
    Cell Signalling Laboratory, Department of Human Anatomical Sciences, University of Bologna, Bologna, Italy
    J Cell Physiol 221:232-41. 2009
    ....
  68. pmc The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:205-12. 2009
    ..The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available...
  69. ncbi Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients
    G Visani
    Institute of Hematology and Medical Oncology 'L and A Seragnoli, Bologna University, Bologna, Italy
    Bone Marrow Transplant 27:829-35. 2001
    ..02). We conclude that the double-FLAN reinforcement strategy is safe and enhances the clinical impact of auto-SCT for AML patients in first complete remission. It may provide specific clinical benefit for patients undergoing auto-SCT...
  70. ncbi Nuclear factor-erythroid 2 (NF-E2) expression in normal and malignant megakaryocytopoiesis
    L Catani
    Istituto di Ematologia e Oncologia Medica L e A Seragnoli, University of Bologna, Bologna, Italy
    Leukemia 16:1773-81. 2002
    ..These two findings provide strong indirect evidence of altered activity of the a isoform of NF-E2 in malignant megakaryocytes, raising the possibility that NF-E2 could play a role in megakaryocyte transformation...
  71. ncbi Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation
    G Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 85:653-8. 2000
    ....
  72. doi Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
    Antonio Curti
    Institute of Hematology, Department of Hematology and Oncological Sciences L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Blood 118:3273-9. 2011
    ..In conclusion, infusion of purified NK cells is feasible in elderly patients with high-risk acute myeloid leukemia. This trial was registered at www.clinicaltrial.gov as NCT00799799...
  73. ncbi Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology, University of Bologna, 40138 Bologna, Italy
    Clin Adv Hematol Oncol 6:303-10. 2008
    ..Early results from studies combining tipifarnib with imatinib or etoposide in CML and AML have been promising and warrant further evaluation in larger clinical trials...
  74. ncbi Advances in the treatment for haematological malignancies
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    Expert Opin Pharmacother 7:721-32. 2006
    ..Although these novel therapies are beginning to fulfil their promise, continued research efforts are needed to determine the optimal role of these strategies in haemato-oncology...
  75. doi New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia
    Giovanni Martinelli
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Rev Hematol 2:297-303. 2009
    ..New therapeutic approaches are now available, such as dasatinib, nilotinib and bosutinib, and we highlight those that may be applicable to the treatment of adult BCR-ABL1-positive ALL...
  76. doi New targets for Ph+ leukaemia therapy
    Giovanni Martinelli
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Best Pract Res Clin Haematol 22:445-54. 2009
    ..In this review, we highlight the most promising drugs for the treatment of adult BCR-ABL-positive leukaemias...
  77. ncbi Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  78. ncbi Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia
    Gianantonio Rosti
    L and A Seràgnoli Institute of Hematology and Medical Oncology, St Orsola Malpighi Hospital, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 88:256-9. 2003
    ....
  79. ncbi The cytogenetic response as a surrogate marker of survival
    Gianantonio Rosti
    Institute of Hematology and Clinical Oncology Seràgnoli Bologna University, Bologna, Italy
    Semin Hematol 40:56-61. 2003
    ..Low-risk patients survive longer than non-low-risk patients given the same CgR. Preliminary results from studies with imatinib are superior and CgR remains an important surrogate marker of survival in the imatinib era...
  80. ncbi A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia
    Michele Baccarani
    L and A Seràgnoli Institute of Hematology and Medical Oncology, S Orsola Hospital, University of Bologna, Italy
    Blood 99:1527-35. 2002
    ....
  81. ncbi Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR28. 2003
  82. doi Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    Gianantonio Rosti
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, 40138 Bologna, Italy
    Blood 114:4933-8. 2009
    ..Nilotinib is safe and very active in early chronic-phase CML. These data support a role for nilotinib for the frontline treatment of CML. This study was registered at ClinicalTrials.gov as NCT00481052...
  83. ncbi Novel FLT3 point mutation in acute myeloid leukaemia
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, Italy
    Lancet Oncol 4:604. 2003
  84. ncbi Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Opin Biol Ther 6:1011-22. 2006
    ..In addition, preliminary experiences with novel tyrosine kinase inhibitors in imatinib-resistant Ph+ ALL are discussed...
  85. doi Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients
    I Iacobucci
    Department of Institute of Hematology and Medical Oncology, L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna 9 40138, Italy
    Leukemia 24:66-73. 2010
    ..In conclusion, BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that may act as mutators outside the immunoglobulin (Ig) gene loci in promoting genetic instability...
  86. ncbi Role of intensive therapy in liver transplant recipients: experience in blood purification and biosynthetic techniques
    S Faenza
    Department of Surgery, University of Bologna, Bologna, Italy
    Transplant Proc 36:555-7. 2004
    ..The aim of this work was to provide a summary of our clinical findings and current methods in extracorporeal liver support with the goal of improving the clinical status potential transplant patients...
  87. ncbi Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center
    B Nardo
    Department of Surgery, ICU and Transplantation, University of Bologna, Bologna, Italy
    Transplant Proc 36:645-7. 2004
    ..However, the most compromised patients are more likely to display intraoperative risks, postoperative complications, and worsening of extracardiac, extrahepatic symptoms...
  88. ncbi Interleukin-4 downregulates nuclear factor-erythroid 2 (NF-E2) expression in primary megakaryocytes and in megakaryoblastic cell lines
    L Catani
    Istituto di Ematologia e Oncologia Medica L e A Seragnoli, University of Bologna Italy
    Stem Cells 19:339-47. 2001
    ..Thus, the results of the present investigation demonstrate that NF-E2 transcription factor is involved not only in terminal megakaryocyte maturation but also in the negative regulation of the early phase of megakaryocyte development...
  89. ncbi Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia
    G Visani
    Institute of Haematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Br J Haematol 109:722-8. 2000
    ..7 (range 2-61) vs. 6.4 (range 1-16) months without FLAN]. We conclude that FLAN induction therapy followed by early allo-SCT appears to be effective in the treatment of BP-CML and could provide a curative possibility for BP-CML patients...
  90. ncbi All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia
    G Visani
    Institute of Hematology and Medical Oncology, Seragnoli University of Bologna, Italy
    Eur J Haematol 64:139-44. 2000
    ..7; p = 0.01), with a disease free survival at 2 yr of 67% vs. 31%. In conclusion, ATRA appears to be able to significantly reduce the incidence of EHD, increasing the number of possible long-term remissions...
  91. ncbi Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma
    M Cavo
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Blood 96:355-7. 2000
    ..It is concluded that allo SCT has the potential ability to induce sustained serological and molecular CR in selected patients with multiple myeloma...
  92. ncbi Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study
    R M Lemoli
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Br J Haematol 107:419-28. 1999
    ..Sequential positive and negative enrichment of stem cells reduced tumour cell contamination in B-cell malignancies below the lower limit of detection of molecular analysis...
  93. ncbi 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features
    N Testoni
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Haematologica 84:690-4. 1999
    ..We reviewed the biological and clinical features of 10 cases of AML with inv(3)(q21q26) and t(3;3)(q21;q26)...
  94. ncbi Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients
    G Visani
    Institute of Haematology and Medical Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Br J Haematol 105:775-9. 1999
    ..We conclude that fludarabine-containing regimens severely impair mobilization and collection of PBSC in AML patients and seem unsuitable when PBSC autotransplantation is programmed...
  95. ncbi Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy
    G Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Haematologica 83:985-8. 1998
    ....
  96. ncbi Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis
    G Martinelli
    Institute of Haematology and Medical Oncology, Seragnoli University of Bologna, Italy
    Haematologica 83:593-601. 1998
    ....
  97. ncbi Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
    P L Tazzari
    Servizio di Immunoematologia e Trasfusionale, Policlinico S Orsola Malpighi, Bologna, Italy
    Leukemia 21:427-38. 2007
    ..Taken together, these data suggest that PI3K/Akt activation may lead to the development of chemoresistance in AML blasts through a mechanism involving a p53-dependent suppression of MRP1 expression...
  98. doi Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
    Nicoletta Testoni
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna and S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 114:4939-43. 2009
    ..I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  99. doi Imatinib mesylate for the treatment of chronic myeloid leukemia
    Simona Soverini
    Department of Hematology and Oncological Sciences Lorenzo e Ariosto Seràgnoli University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Expert Rev Anticancer Ther 8:853-64. 2008
    ..Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients...
  100. ncbi Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase
    Laura Pattacini
    Istituto di Ematologia e Oncologia Medica, Lorenzo e Ariosto Seràgnoli, Università di Bologna Medical School, S Orsola Hospital, Via Massarenti 9, Bologna 40138, Italy
    Leuk Res 28:191-202. 2004
    ....
  101. ncbi Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells
    V Papa
    Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell Apparato Locomotore, Universita di Bologna, Bologna, Italy
    Leukemia 22:147-60. 2008
    ..Our findings indicate that perifosine, either alone or in combination with existing drugs, might be a promising therapeutic agent for the treatment of those AML cases characterized by upregulation of the PI3K-Akt survival pathway...